Qelbree viloxazine approval date?

Qelbree (viloxazine) was approved by the U.S. Food and Drug Administration (FDA) on April 20, 2021 [1].

What is Qelbree approved to treat?

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients aged 6 to 17 years [1].

What is the active ingredient in Qelbree?

The active ingredient in Qelbree is viloxazine [1].

When did viloxazine become available as a treatment?

Viloxazine, under the brand name Qelbree, became available following its FDA approval in April 2021 [1].

What is the mechanism of action for viloxazine?

The exact mechanism by which viloxazine exerts its therapeutic effects in ADHD is not fully understood, but it is believed to involve the potentiation of norepinephrine signaling in the brain by acting as a selective norepinephrine reuptake inhibitor [1].